Professor of Medicine
Centre de recherche du CHUM and University of Montreal
Basic Science
Immunology, Fibrosis

Centre de Recherche du CHUM

Tour Viger, Local R09.414
900 rue St-Denis
Montréal, QC H2X 0A9

(514) 890-8000 ext 35235

Dr. Naglaa H. Shoukry is  a viral immunologist (Ph.D. McGill, 2000) who is recognized as a world leader in human immunology, specifically immunity to hepatitis C virus (HCV) (>78 publications). Research accomplished during her post-doctoral training established the essential and complementary roles of CD8+ and CD4+ T cells in resolution and protection from persistent HCV infection in the chimpanzee non-human primate model (Grakoui et al., 2003; Shoukry et al., 2003). Since 2005, she has established her independent group at the University of Montreal Hospital Centre (CRCHUM) and a translational research program focused on studying immunity to HCV using unique patient cohorts like people who inject drugs (PWIDs) at high risk of HCV infection. More recently, her research has expanded to studying immunological mechanisms of liver inflammation and fibrosis progression and development of hepatocellular carcinoma (HCC).  Her research was/is funded by the Canadian Institutes of Health Research (CIHR), Fonds de recherche du Québec – Santé (FRQS), the Dana Foundation, the Canadian Foundation for Aids Research (CANFAR), the Canadian Liver Foundation (CLF) and the National Institutes of Health (NIH). She has received numerous awards from the American Liver Foundation, CIHR and FRQS. She has served on various review committees on the national and international level including CIHR, FRQS, CRC, NIH, Wellcome Trust, MRC and DFG. I am an Academic Editor for PLoS One, Viral Immunology and Frontiers in Immunology. In recognition, CIHR profiled her achievements on World Hepatitis Day in 2013 and 2017. In 2019, she was selected as Professor of the Year by the Department of Medicine, University of Montreal and was awarded the CLF 50th Anniversary Recognition Medal.

Dr. Shoukry has been a mentor in the National Canadian Research Training Program on Hepatitis C (NCRTP-HepC) since 2005. In June 2014, she was selected as the co-director of the NCRTP-HepC and led the CIHR application to create the Canadian Network on Hepatitis C (CanHepC). She is the Nominated Principal Investigator of the CanHepC Network

Research Program

Chronic liver disease and advanced liver fibrosis, known as cirrhosis, has nearly doubled in Canada over the past two decades. Liver fibrosis is multifactorial and occurs in response to liver injury due to toxins, alcohol consumption, viral hepatitis (B and C) infection and non-alcoholic fatty liver disease (NAFLD). Cirrhosis is the main risk for developing liver cancer or hepatocellular carcinoma (HCC). HCC is on the rise in North America. Direct acting antivirals (DAAs) that completely cure hepatitis C virus (HCV) are expected to decrease HCV-related fibrosis. However, it is not clear if this will reverse fibrosis and impact the incidence of HCC especially in individuals with cirrhosis. Furthermore, the rising rates of obesity are expected to cause an increase in NAFLD-related liver disease and HCC.

Since joining the CRCHUM in 2005, our group has established a translational research program in liver immunology focused on immunity against hepatitis C virus (HCV). In collaboration with clinicians at the CRCHUM, we have built a unique cohort of patients at different stages of HCV infection and a biobank that has allowed us to address key questions in HCV immuno-pathology. Recognizing the increased incidence of advanced liver disease and liver cancer with various aetiologies, our program has broadened to study immunological mechanisms of liver fibrosis and HCC. Our research program has two complementary research themes:

1.     To identify correlates of protective immunity against HCV in high-risk people who inject drugs (PWID) and define parameters/signatures to be used as benchmark to measure efficacy of new HCV vaccines. This theme uses high-resolution immunological and transcriptomic approaches to define these protective signatures and interactions between the T cell and B cell arms of the immune response.

2.     To understand immunological mechanism of liver disease progression and onset of liver cancer, with a focus on the immunological landscape and cytokines that may favor cancer development and/or dampen the immune response against cancer cells and how such factors influence the response to novel anti-cancer immunotherapies.


Lab Facebook page